ID

13118

Descripción

Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01133704

Link

https://clinicaltrials.gov/show/NCT01133704

Palabras clave

  1. 17/1/16 17/1/16 -
Subido en

17 de enero de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Hormone-Refractory Prostate Cancer NCT01133704

Eligibility Hormone-Refractory Prostate Cancer NCT01133704

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically documented adenocarcinoma of the prostate
Descripción

prostate adenocarcinoma

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0019638
UMLS CUI [1,2]
C0007112
metastatic disease as evidenced by soft tissue and/or bony metastases
Descripción

metastasis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0027627
prostate-specific antigen value of at least 5 ng/ml
Descripción

psa

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0138741
tumor progression while on hormonal therapy
Descripción

tumor progression while on hormone therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0178874
UMLS CUI [1,2]
C0279025
castration levels of testosterone (defined as less than 50 ng/dl)
Descripción

testosterone

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0523912
life expectancy of at least 16 weeks
Descripción

life expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
adequate hematologic, renal, and liver function
Descripción

organ function

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0232741
UMLS CUI [1,2]
C0005953
UMLS CUI [1,3]
C0232804
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
visceral organ metastases
Descripción

visceral metastases

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C0442045
metastatic disease expected to be in need of radiation therapy within 4 months.
Descripción

radiation therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1522449
concurrent therapy with experimental agents
Descripción

study subject participation status, concurrent therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0009429

Similar models

Eligibility Hormone-Refractory Prostate Cancer NCT01133704

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
prostate adenocarcinoma
Item
histologically documented adenocarcinoma of the prostate
boolean
C0019638 (UMLS CUI [1,1])
C0007112 (UMLS CUI [1,2])
metastasis
Item
metastatic disease as evidenced by soft tissue and/or bony metastases
boolean
C0027627 (UMLS CUI [1])
psa
Item
prostate-specific antigen value of at least 5 ng/ml
boolean
C0138741 (UMLS CUI [1])
tumor progression while on hormone therapy
Item
tumor progression while on hormonal therapy
boolean
C0178874 (UMLS CUI [1,1])
C0279025 (UMLS CUI [1,2])
testosterone
Item
castration levels of testosterone (defined as less than 50 ng/dl)
boolean
C0523912 (UMLS CUI [1])
life expectancy
Item
life expectancy of at least 16 weeks
boolean
C0023671 (UMLS CUI [1])
organ function
Item
adequate hematologic, renal, and liver function
boolean
C0232741 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0232804 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
visceral metastases
Item
visceral organ metastases
boolean
C0027627 (UMLS CUI [1,1])
C0442045 (UMLS CUI [1,2])
radiation therapy
Item
metastatic disease expected to be in need of radiation therapy within 4 months.
boolean
C1522449 (UMLS CUI [1])
study subject participation status, concurrent therapy
Item
concurrent therapy with experimental agents
boolean
C2348568 (UMLS CUI [1])
C0009429 (UMLS CUI [2])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial